# **An Overview of Class II Phosphoinositide 3-Kinases**



**Emily Yan Zhi Heng and Tania Maffucci** 

# **Contents**



**Abstract** Phosphoinositide 3-kinases (PI3Ks) catalyse the synthesis of specific members of the family of lipids collectively known as 'phosphoinositides'. These PI3Ks products can in turn modulate activation of many downstream proteins, ultimately regulating several cellular processes. Mammalian cells possess eight PI3Ks which are grouped into three classes based on their structure and substrate specificity. While class I and III PI3Ks have been extensively investigated, our understanding of the three class II members has only improved in most recent years. This chapter will summarise some of the available information on mammalian class II PI3Ks and their physiological roles.

E. Y. Z. Heng  $\cdot$  T. Maffucci  $(\boxtimes)$ 

Centre for Cell Biology and Cutaneous Research, Blizard Institute, Faculty of Medicine and Dentistry, Queen Mary University of London, 4 Newark Street, London E1 2AT, UK e-mail: [t.maffucci@qmul.ac.uk](mailto:t.maffucci@qmul.ac.uk)

<sup>©</sup> The Author(s), under exclusive license to Springer Nature Switzerland AG 2022 M. Dominguez-Villar (ed.), *PI3K and AKT Isoforms in Immunity*, Current Topics in Microbiology and Immunology 436, https://doi.org/10.1007/978-3-031-06566-8\_2

## <span id="page-1-1"></span><span id="page-1-0"></span>**List of Abbreviations**



## <span id="page-1-2"></span>**1 Introduction**

Phosphoinositide 3-kinases (PI3Ks) are a conserved family of lipid kinases that catalyse the phosphorylation of specific phosphoinositides (Cantley [2002;](#page-14-0) Vanhaesebroeck et al. [2012;](#page-17-0) Maffucci [2012](#page-15-0)), a group of lipids consisting of a *myo*inositol headgroup linked to a diacylglycerol (DAG) through a phosphodiester bond (Fig. [1\)](#page-2-2). Specifically, PI3Ks catalyse phosphorylation on position three within the *myo*-inositol ring of phosphatidylinositol (PtdIns), phosphatidylinositol 4-phosphate (PtdIns4*P*) and phosphatidylinositol 4,5-bisphosphate [PtdIns $(4,5)P_2$ ], leading to the synthesis of phosphatidylinositol 3-phosphate (PtdIns3*P*), phosphatidylinositol 3,4-bisphosphate  $[PtdIns(3,4)P_2]$  and phosphatidylinositol 3,4,5-trisphosphate [PtdIns(3,4,5)*P3*], respectively (Vanhaesebroeck et al. [2001](#page-17-1); Domin and Waterfield [1997\)](#page-14-1) (Fig. [1\)](#page-2-2). These lipids in turn regulate the activation of several proteins, ultimately controlling a plethora of intracellular functions (Vanhaesebroeck et al. [2010,](#page-17-2) [2016;](#page-17-3) Engelman et al. [2006](#page-14-2); Ghigo et al. [2012;](#page-15-1) Falasca and Maffucci [2007](#page-14-3), [2012](#page-15-2); Gulluni et al. [2019](#page-15-3); Bilanges et al. [2019](#page-14-4)). Eight mammalian PI3Ks exist and they were grouped into three classes based on their structure and substrate specificity (Vanhaesebroeck et al. [2001;](#page-17-1) Domin and Waterfield [1997\)](#page-14-1). Class I PI3Ks, by far

<span id="page-2-1"></span>

<span id="page-2-2"></span>**Fig. 1** Schematic representation of the lipid substrates and products of the distinct classes of PI3Ks. Positions within the inositol ring are indicated by numbers

the best characterised amongst the members of this family, are dimers of a regulatory and one of four catalytic subunits, and are mainly responsible for synthesis of PtdIns $(3,4,5)P_3$  in vivo. Class II PI3Ks have been reported to catalyse synthesis of both PtdIns3*P* and PtdIns(3,4)*P2*. Class III PI3K catalyses synthesis of the bulk of intracellular PtdIns3*P* (Fig. [1](#page-2-2)).

For a long time, class II PI3Ks have been the least investigated amongst all PI3Ks but our understanding of these enzymes has massively improved in most recent years. This chapter will focus on mammalian class II PI3Ks and their physiological roles. It must be noted, however, that accumulating data in literature also points to a role for them in several human diseases (Vanhaesebroeck et al. [2016;](#page-17-3) Ghigo et al. [2012](#page-15-1); Falasca and Maffucci [2012](#page-15-2); Gulluni et al. [2019](#page-15-3); Bilanges et al. [2019\)](#page-14-4).

#### <span id="page-2-0"></span>**2 Identification and Tissue Distribution**

A class II PI3K was first identified in *Drosophila melanogaster* (MacDougall et al. [1995\)](#page-15-4). It was later discovered that class II enzymes are conserved from *Caenorhabditis elegans* to humans but they are not expressed in yeast [reviewed in Gulluni <span id="page-3-1"></span>et al. ([2019\)](#page-15-3), Bilanges et al. [\(2019](#page-14-4)), Margaria et al. [\(2019](#page-16-0))]. Three members of class II PI3Ks exist in mammalian cells, namely PI3K-C2α, PI3K-C2β and PI3K-C2γ, encoded by the genes *PIK3C2A*, *PIK3C2B* and *PIK3C2G*, respectively. Human PI3K-C2α was cloned from U937 cells (Domin et al. [1997\)](#page-14-5) while human PI3K-C2β was isolated from a cDNA library of MCF7 (Brown et al. [1997\)](#page-14-6) and subsequently from U937 cells (Arcaro et al. [1998\)](#page-13-3). Original studies indicated that PI3K-C2α was ubiquitously expressed with highest levels in heart, placenta and ovary (Domin et al. [1997\)](#page-14-5). Expression of PI3K-C2β was shown to be high in thymus and placenta, while expression of PI3K-C2 $\gamma$  was identified in liver and prostate tissue as well as in breast and salivary glands (Rozycka et al. [1998;](#page-16-1) Ono et al. [1998\)](#page-16-2). It is now well established that PI3K-C2α and PI3K-C2β are ubiquitously expressed while PI3K-C2γ shows a more restricted expression pattern (Consortium GTEx [2013\)](#page-14-7). Interestingly, a recent study reported an increase of PI3K-C2β both at the mRNA and protein levels in fibroblasts obtained from individuals carrying homozygous loss-of-function mutations in *PIK3C2A* as well as upregulation of PI3K-C2β upon downregulation of PI3K-C2 $α$  in HeLa cells (Tiosano et al. [2019](#page-17-4)). Whether this is a compensatory effect or whether this study has unveiled a general mechanism of regulation of the expression levels of these two enzymes remains to be established. PI3K-C2 $\gamma$  levels can also be modulated, as suggested by a study reporting increased expression of this enzyme during liver regeneration following partial hepatectomy (Ono et al. [1998](#page-16-2)).

#### <span id="page-3-0"></span>**3 Structure of Class II PI3Ks**

Class II PI3Ks are monomers of high molecular weight, possessing the PI3K core common to all family members (consisting of a C2 domain, a helical domain and the catalytic domain), a Ras binding domain (also found on the catalytic subunits of class I PI3Ks) but characterised by unique N-terminal and C-terminal extensions compared to the other PI3Ks (Fig. [2](#page-3-2)) (Vanhaesebroeck et al. [2010](#page-17-2); Falasca and Maffucci [2012](#page-15-2); Gulluni et al. [2019](#page-15-3); Margaria et al. [2019\)](#page-16-0). The C-terminal extension is common between the three class II PI3Ks and consists of a Phox homology (PX) domain and a C2 domain (Fig. [2](#page-3-2)). The N-terminal extensions differ between the three enzymes and allow some of them to bind to distinct proteins. For instance,



<span id="page-3-2"></span>**Fig. 2** Schematic representation of the common structure of class II PI3Ks, comprising an Nterminal region, a Ras binding domain, the PI3K core (consisting of a C2, a helical and a catalytic domain) and a common C-terminal, comprising a PX and a second C2 domain

<span id="page-4-1"></span>both PI3K-C2α (Gaidarov et al. [2001](#page-15-5)) and PI3K-C2β (Wheeler and Domin [2006\)](#page-17-5) can bind to clathrin via their N-terminal region, but PI3K-C2β can also interact with Raptor (Marat et al. [2017](#page-15-6)). In addition, PI3K-C2β possesses proline-rich motifs which have been investigated for their potential role in activation of the enzyme (Wheeler and Domin [2006](#page-17-5)), while PI3K-C2 $\alpha$  can bind to transforming acidic coiledcoil-containing protein 3 (TACC3) via a region localised between the Ras binding domain and the PI3K core (Gulluni et al. [2017](#page-15-7)). Less is known about the structure of PI3K-C2γ which, in general, is the least characterised of the three enzymes, but it does not appear to possess a clathrin binding domain (Margaria et al. [2019](#page-16-0)).

#### <span id="page-4-0"></span>**4 Lipid Products**

The differences between class II and class I PI3K enzymes were immediately clear, as indicated by an original study reporting that only 1% of the in vitro activity of PI3K-C2β was directed towards PtdIns(4,5)*P2* (Arcaro et al. [1998](#page-13-3)), the main substrate of class I PI3Ks. On the other hand, class II PI3Ks were found to catalyse phosphorylation of PtdIns and PtdIns4*P* (MacDougall et al. [1995](#page-15-4); Arcaro et al. [1998,](#page-13-3) [2000;](#page-13-4) Gaidarov et al. [2001;](#page-15-5) Virbasius et al. [1996;](#page-17-6) Misawa et al. [1998\)](#page-16-3), with PtdIns being the main substrate in vitro (Falasca and Maffucci [2012](#page-15-2)). While it was soon clear that PtdIns3*P* and, to a lesser extent, PtdIns $(3,4)P_2$ , were the main products of class II PI3Ks in vitro, identification of their in vivo products was complicated by the absence of selective inhibitors for these enzymes. Indeed, data only started appearing following the advent of antisense/siRNAs/shRNAs-based techniques and, later on, with the generation of transgenic mice (Falasca et al. [2007;](#page-15-8) Maffucci et al. [2005;](#page-15-9) Wen et al. [2008](#page-17-7); Boukhalfa et al. [2020a](#page-14-8), [b](#page-14-9); Valet et al. [2015](#page-17-8); Alliouachene et al. [2015](#page-13-5); Franco et al. [2014;](#page-15-10) Yoshioka et al. [2012](#page-17-9)).

#### <span id="page-4-2"></span>*4.1 PtdIns3P*

Over fifteen years ago, we reported that  $PI3K-C2\alpha$  and  $PI3K-C2\beta$  catalyse the synthesis of PtdIns3*P* in vivo in response to insulin (Falasca et al. [2007](#page-15-8)) and lysophosphatidic acid (LPA) (Maffucci et al. [2005\)](#page-15-9). These studies were amongst the first lines of evidence supporting a role for class II PI3Ks in the regulation of pools of PtdIns3*P* specifically synthesised in response to cellular stimulation. Consistent with this, PI3K-C2α-dependent pools of PtdIns3*P* were also detected in PC12 cells upon stimulation of exocytosis (Wen et al. [2008](#page-17-7)) and have been observed, more recently, in kidney epithelial cells in response to shear stress (Boukhalfa et al. [2020a,](#page-14-8) [b\)](#page-14-9). The possibility of a cell cycle-dependent, class II PI3Ks-mediated synthesis of this phosphoinositide was also supported by in vitro assays demonstrating that PtdIns3*P*, but not PtdIns $(4,5)P_2$  or PtdIns $(3,4,5)P_3$ , increased in the nuclei and nuclear <span id="page-5-1"></span>envelopes of HL-60 cells during transition into the G2/M-phase, likely due to activa-tion of PI3K-C2β (Visnjić et al. [2003\)](#page-17-10). Transgenic mouse models revealed that class II PI3Ks can also regulate pools of PtdIns3*P* in basal, unstimulated conditions, as detected in platelets from mice heterozygous for a catalytically inactive (kinase-dead) PI3K-C2 $\alpha$  (Valet et al. [2015\)](#page-17-8) or in unstimulated hepatocytes from a mouse model expressing a kinase-dead PI3K-C2β (Alliouachene et al. [2015](#page-13-5)). This latter study further indicated that PI3K-C2β modulation of PtdIns3*P* was cell type-specific, as levels of this phosphoinositide were reduced in hepatocytes but not in mouse embryo fibroblasts (MEFs) or splenocytes (Alliouachene et al. [2015](#page-13-5)).

Generally, class II PI3Ks have been implicated in localised synthesis of PtdIns3*P*  within specific cellular compartments. For instance, the previously mentioned insulin- and LPA-dependent PtdIns3*P* was detected at the plasma membrane (Falasca et al. [2007](#page-15-8); Maffucci et al. [2005](#page-15-9)). Similarly, PtdIns3*P* was specifically generated in large dense-core vesicles (Wen et al. [2008\)](#page-17-7) or in the primary cilium area (Boukhalfa et al. [2020b\)](#page-14-9) during exocytosis and in response to shear stress, respectively. Furthermore, MEFs lacking PI3K-C2α displayed reduced levels of a basal pool of PtdIns3*P*  specifically localised around the base of the cilium but showed no alteration on this phosphoinositide within the rest of the cell (Franco et al. [2014](#page-15-10)). Similarly, selective ablation of PI3K-C2 $\alpha$  in endothelial cells was shown to decrease the levels of PtdIns3*P* in endosomes (Yoshioka et al. [2012](#page-17-9)). Taken together these studies indicate that PI3K-C2α and PI3K-C2β can control synthesis of very localised pools of PtdIns3*P*, sometimes in response to specific cellular stimulation. To the best of our knowledge, there is no indication so far that  $PI3K-C2\gamma$  can also catalyse synthesis of PtdIns3*P* in vivo.

## <span id="page-5-0"></span>*4.2 PtdIns(3,4)P***<sup>2</sup>**

PtdIns(3,4) $P_2$  is the only in vivo product of PI3K-C2 $\gamma$  identified so far, and it appears to be localised specifically on Rab5-positive early endosomes (Braccini et al. [2015](#page-14-10)). Evidence that the other class II PI3Ks can also catalyse the synthesis of PtdIns(3,4)*P*<sub>2</sub> in vivo also exists, including the observation that transient downregulation of PI3K-C2 $\alpha$  inhibited the insulin-induced synthesis of PtdIns(3,4)*P<sub>2</sub>*, but not PtdIns(3,4,5)*P<sub>3</sub>* or levels of PtdIns3*P* in MIN6 pancreatic β cells (Leibiger et al. [2010](#page-15-11)) and more recent data indicating that PI3K-C2α and PI3K-C2β catalyse the synthesis of PtdIns(3,4)*P2*  at late-stage endocytic compartments (Posor et al. [2013\)](#page-16-4) and in lysosomes and late endosomes (Marat et al. [2017\)](#page-15-6). Consistent with this, fibroblasts derived from patients displaying homozygous loss-of-function mutations in *PIK3C2A* revealed reduced PtdIns(3,4)*P2* overall and reduced PtdIns3*P* specifically at the ciliary base (Tiosano et al. [2019](#page-17-4)).

## <span id="page-6-1"></span><span id="page-6-0"></span>**5 Mechanisms of Activation**

Although our understanding of the physiological roles of class II PI3Ks has improved massively in the past decade, still little is known about the mechanisms of their activation (Falasca and Maffucci [2012;](#page-15-2) Bilanges et al. [2019](#page-14-4)). Association of class II PI3Ks to some growth factor receptors was reported (Falasca and Maffucci [2012\)](#page-15-2), such as interaction of PI3K-C2α and PI3K-C2β with the epidermal growth factor receptor (EGFR) (Arcaro et al. [2000\)](#page-13-4), of PI3K-C2 $\alpha$  with the insulin receptor B (Leibiger et al. [2010\)](#page-15-11), and of PI3K-C2β with the platelet-derived growth factor receptor (Arcaro et al. [2000\)](#page-13-4) and c-Kit (Arcaro et al. [2002](#page-13-6)). This, however, has not led to a clear indication of whether such associations are part of a generic mechanism of activation of these enzymes, as well established for class I PI3Ks. In this respect, it is worth mentioning that binding of PI3K-C2α and PI3K-C2β to EGFR and ErbB-2 was already detectable in quiescent A431 cells although it increased upon EGF stimulation (Arcaro et al. [2000\)](#page-13-4) and association of PI3K-C2β with c-Kit in small cell lung carcinoma cell lines did not appear to increase upon stem cell factor stimulation (Arcaro et al. [2002](#page-13-6)).

Original studies reported that the in vitro activity of PI3K-C2α increased upon removal of the region encompassing the clathrin-binding sites (Gaidarov et al. [2001\)](#page-15-5) and that deletion of the proline-rich motifs of PI3KC2β affected its activity (Wheeler and Domin [2006\)](#page-17-5), suggesting that the N-terminal extensions could be involved in regulation of their enzymatic activity. On the other hand, the involvement of the Cterminal PX and C2 domains in regulation of PI3K-C2 $\alpha$  activation has been demonstrated by a recent study showing that these two domains fold onto the catalytic domain preventing its activity when the enzyme is in solution (Wang et al. [2018](#page-17-11)). Once the enzyme is recruited to the membrane, interactions of the N-terminal region with clathrin and of both PX and C2 domains with PtdIns $(4,5)P_2$  remove such an inhibition over the catalytic domain (Wang et al. [2018\)](#page-17-11). Interestingly,  $Ca^{2+}$  has been reported to affect the interaction of PI3K-C2α PX-C2 domains with the membrane (Chen et al. [2018\)](#page-14-11) and previous studies demonstrated that the activity of this enzyme could be increased by increasing concentration of  $Ca^{2+}$  (Wen et al. [2008\)](#page-17-7) and by stimuli able to increase intracellular  $Ca^{2+}$  concentration (Wang et al. [2006\)](#page-17-12). Currently, it is not known whether such an autoregulatory mechanism exists in all class II enzymes although it is worth mentioning that increased enzymatic activity of PI3K-C2β in vitro was observed upon deletion of the C-terminal C2 domain (Arcaro et al. [1998\)](#page-13-3). Being the PX/C2 domains a characteristic feature of class II PI3Ks, it is tempting to speculate that this or similar mechanisms might regulate the activation of all class II PI3Ks.

Association with other proteins has been also proposed as a potential mechanism of activation (Falasca and Maffucci [2012\)](#page-15-2), as in the case of PI3K-C2β and intersectin (Das et al. [2007\)](#page-14-12). More recently, a study demonstrated that protein kinase N induces PI3K-C2β inactivation upon mitogen stimulation by promoting its association to 14-3-3 proteins (Wallroth et al. [2019](#page-17-13)). Evidence of post-translational modifications of PI3K-C2β is also present in the literature, from growth factor-induced tyrosine phosphorylation (Arcaro et al. [2002\)](#page-13-6) to possible proteolysis (Visnjić et al. [2003](#page-17-10)) and <span id="page-7-1"></span>nitrotyrosylation (Chiang and Postlethwaite [2006\)](#page-14-13). The specific role of these posttranslational modifications in the modulation of class II PI3Ks enzymatic activity, however, remains to be clarified.

As discussed previously, an interesting aspect of class II PI3Ks biology is their ability to generate localised pools of PtdIns $3P$  and PtdIns $(3,4)P_2$ . Consistent with this, studies have reported intracellular relocation of class II enzymes as the way by which such localised synthesis of their products can be achieved. Examples include the insulin-induced translocation of a GFP-tagged PI3K-C2 $\alpha$  to the plasma membrane of L6 cells (Falasca et al. [2007](#page-15-8)), the LPA-dependent translocation of a Myc-tagged PI3KC2β to the plasma membrane of HeLa and SKOV-3 cells (Maffucci et al.  $2005$ ) and the shear stress-induced relocation of PI3K-C2 $\alpha$  to the primary cilium (Boukhalfa et al. [2020b\)](#page-14-9).

Much work is still required to come to a full understanding of how the enzymatic activity of class II PI3Ks can be modulated in different cellular contexts.

# <span id="page-7-0"></span>**6 Physiological Roles of Class II PI3Ks—Insights from Animal Models**

## <span id="page-7-2"></span>*6.1 PI3K-C2α*

Our understanding of the physiological roles of class II PI3Ks has improved in the past ten years due to the generation of several mouse models, as recently summarised (Gulluni et al. [2019](#page-15-3)). Briefly, a critical role for PI3K-C2 $\alpha$  during development was demonstrated by two studies reporting embryonic lethality upon full knockout of the enzyme, due to defects at the level of the primary cilium structure and function (Franco et al. [2014](#page-15-10)) and in vascular development and angiogenesis due to its key role in endothelial cells specifically (Yoshioka et al. [2012](#page-17-9)). Embryonic lethality was also reported in homozygous mouse models for either a kinase-dead (Alliouachene et al. [2016](#page-13-7)) or truncated versions (Mountford et al. [2015](#page-16-5)) of PI3K-C2α. Heterozygous mice from the kinase-dead model were viable and fertile although male mice presented early onset leptin resistance, mild age-dependent obesity, insulin resistance and glucose intolerance (Alliouachene et al. [2016](#page-13-7)). Heterozygous mice expressing the truncated versions of PI3K-C2 $\alpha$  showed alteration of the internal membrane structure of platelets and impaired thrombosis (Mountford et al. [2015](#page-16-5)). These defects were not detected in platelets from PI3K-C2β deficient mice and were not enhanced in platelets from mice deficient in both enzymes (Petitjean et al. [2016](#page-16-6)), confirming a non-redundant role for PI3K-C2α in platelets.

### <span id="page-8-1"></span><span id="page-8-0"></span>*6.2 PI3K-C2β*

In contrast to PI3K-C2α, a PI3K-C2β full knockout mouse model was reported to be viable and fertile (Harada et al. [2005\)](#page-15-12). This study focused in particular on the impact on the epidermis and reported no alteration in epidermal growth, differentiation or in the barrier function in knockout mice (Harada et al. [2005](#page-15-12)). Knockout mice were also shown to be resistant to passive cutaneous and passive systemic anaphylaxis (Srivastava et al. [2017](#page-17-14)). A mouse model expressing a kinase-dead PI3K-C2β revealed increased insulin sensitivity selectively in metabolic tissues as well as increased glucose tolerance and protection against liver steatosis induced by high-fat diet (Alliouachene et al. [2015](#page-13-5)).

## <span id="page-8-2"></span>*6.3 PI3K-C2γ*

A PI3K-C2γ global knockout mouse model was also reported to be viable and to develop normally. These mice showed reduced accumulation of glycogen in the liver and altered lipid metabolism and developed insulin resistance with age or upon high-fat diet (Braccini et al. [2015](#page-14-10)).

# <span id="page-8-3"></span>**7 Physiological Roles of Class II PI3Ks—First Insight from Human Studies**

A recent study reported the identification of the first monogenic disorder linked to mutations of a class II PI3K (Tiosano et al. [2019\)](#page-17-4). The authors described five individuals from three unrelated consanguineous families showing similar clinical features, including short stature, cataracts, dysmorphic facial features, skeletal and teeth abnormalities. Most individuals also presented neurological abnormalities and secondary glaucoma. Hearing loss was also observed in some patients. Nextgeneration sequencing analyses showed that all affected family members, but none of the unaffected members, were homozygous for loss-of-function variants in *PIK3C2A*  and indeed PI3K-C2α was not detected in patient-derived fibroblasts (Tiosano et al. [2019\)](#page-17-4). This study indicated a critical role for PI3K-C2 $\alpha$  in human development but it also highlighted a stark difference with the transgenic mouse models where lack of PI3K-C2α results in embryonic lethality. Whether this difference is due to different physiological roles in humans or potential compensatory effects of other PI3Ks (possibly PI3K-C2β, whose expression levels increase in fibroblasts from affected individuals (Tiosano et al. [2019\)](#page-17-4)) remains to be established.

#### <span id="page-9-1"></span><span id="page-9-0"></span>**8 Cellular Functions Regulated by Class II PI3Ks**

#### <span id="page-9-2"></span>*8.1 PI3K-C2α*

Investigation into the molecular mechanisms responsible for the phenotypes detected in the different animal models revealed that  $P13K-C2\alpha$  is involved in several intracellular trafficking processes, including transport of cargos and signalling proteins to the primary cilium (Franco et al. [2014,](#page-15-10) [2016](#page-15-13)) as well as trafficking of vascular endothelial growth factor receptor-2 and sphingosine-1-phosphate receptor 1 (Yoshioka et al. [2012](#page-17-9)), vascular endothelial-cadherin (Yoshioka et al. [2012\)](#page-17-9) and leptin receptor (Alliouachene et al. [2016\)](#page-13-7). Studies using cell lines also indicated a role in clathrin-dependent (Gaidarov et al. [2001](#page-15-5); Posor et al. [2013](#page-16-4)) and in dynaminindependent endocytosis (Krag et al. [2010](#page-15-14)) as well as in neurosecretory (Wen et al. [2008;](#page-17-7) Meunier et al. [2005](#page-16-7)) and insulin (Leibiger et al. [2010](#page-15-11); Dominguez et al. [2011\)](#page-14-14) granule exocytosis.

Data also indicate the involvement of PI3K-C2α in several different cellular processes, from regulation of vascular smooth muscle cell contraction (Wang et al. [2006;](#page-17-12) Yoshioka et al. [2007\)](#page-17-15) to human cytomegalovirus replication (Polachek et al. [2016\)](#page-16-8) and Kaposi's sarcoma-associated herpesvirus reactivation from latency (Abere et al. [2018](#page-13-8)). PI3K-C2α has been also implicated in regulation of autophagy (Merrill et al. [2017\)](#page-16-9) through its ability to generate a localised pool of PtdIns3*P* which is critical during initiation of this cellular process (Nascimbeni et al. [2017a;](#page-16-10) Roberts and Ktistakis [2013\)](#page-16-11). Recent data, in particular, have revealed a specific role for the PI3K-C2α-dependent PtdIns3*P* pool in shear stress-induced autophagy in kidney epithelial cells, as opposed to the PtdIns3*P* pool generated by class III PI3K which is required for activation of autophagy upon cellular starvation (Boukhalfa et al. [2020b](#page-14-9)).

A role for PI3K-C2α in insulin signalling was also suggested by data demonstrating that its downregulation reduced translocation of the glucose transporter GLUT4 to the plasma membrane and glucose uptake in muscle cells (Falasca et al. [2007\)](#page-15-8) and it induced a switch toward mitogenic rather than metabolic signalling in pancreatic β cells (Leibiger et al.  $2015$ ). On the other hand, heterozygous mice for a kinase-dead PI3K-C2α did not display alteration of insulin signalling in insulin target tissues (Alliouachene et al. [2016](#page-13-7)). Although it cannot be excluded that the different results are due to the partial inactivation of the enzyme as opposed to its downregulation, the potential contribution of PI3K-C2α to insulin signalling requires further investigation.

#### <span id="page-9-3"></span>*8.2 PI3K-C2β*

Compared to PI3K-C2 $\alpha$ , the cellular functions ascribed to PI3K-C2 $\beta$  are somehow more limited, although they seem to be more common between different cell types. For example, PI3K-C2β is involved in regulation of migration of several cell types, <span id="page-10-1"></span>from HEK293 (Domin et al. [2005\)](#page-14-15) and human umbilical vein endothelial cells (Tibolla et al. [2013](#page-17-16)) to different types of cancer cells (Maffucci et al. [2005](#page-15-9); Mavrommati et al. [2016](#page-16-12); Chikh et al. [2016;](#page-14-16) Katso et al. [2006](#page-15-16)). Investigation of the kinase-dead mouse model revealed a role for  $P13K-C2\beta$  in the regulation of insulin signalling pathways through regulation of endosomal trafficking, in particular of the insulin receptor (Alliouachene et al. [2015](#page-13-5)). PI3K-C2β has been also involved in negative regulation of mTORC1 during growth factor deprivation (Marat et al. [2017](#page-15-6)) and it has been proposed as a host factor for influenza virus entry (O'Hanlon et al. [2019](#page-16-13)).

#### <span id="page-10-0"></span>*8.3 PI3K-C2γ*

Investigation of the mechanisms responsible for the defective metabolism detected in PI3K-C2 $\gamma$  knockout mice revealed a role for this enzyme in the regulation of glycogen synthase activity in the liver upon insulin stimulation (Braccini et al. [2015](#page-14-10)). Overall, very little is still known about the physiological roles of PI3K-C2γ, which remains the most obscure of the three class II PI3Ks.

#### <span id="page-10-2"></span>*8.4 Co-operative Roles?*

While most studies indicate distinct functions for class II PI3Ks, evidence of the involvement of both PI3K-C2α and PI3K-C2β in the regulation of some cellular processes has also appeared in the literature. Examples include studies indicating a role for both enzymes in vascular smooth muscle cell contraction (Sarker et al. [2019;](#page-16-14) Islam et al. [2020](#page-15-17)), in clathrin-dependent pinocytosis (Aung et al. [2019](#page-13-9)) and in the regulation of cell mitosis (Gulluni et al. [2017](#page-15-7); Cisse et al. [2019](#page-14-17)). Understanding the relative contribution of each enzyme in these processes will be very interesting. It is known, for example, that they play distinct roles in the regulation of pinocytosis (Aung et al. [2019](#page-13-9)). On the other hand, the exact role of PI3K-C2β during mitosis has not been described yet (Cisse et al. [2019\)](#page-14-17), therefore its involvement in this process is still not clear, in particular, compared to  $PI3K-C2\alpha$ , which is critical for mitotic spindle assembly and anaphase onset (Gulluni et al. [2017\)](#page-15-7). Interestingly, it has been demonstrated that the enzymatic activity of  $PI3K-C2\alpha$  is not required during mitosis as it contributes to the process by acting as a scaffold protein (Gulluni et al. [2017\)](#page-15-7). As the involvement of PI3K-C2β was identified using siRNA/shRNAmediated downregulation (Cisse et al. [2019](#page-14-17)), it remains to be established whether the enzymatic activity of PI3K-C2β is required instead. In general, it will be interesting to define the exact mechanisms of action of each enzyme in cellular processes that involve both of them and to understand why two members of the same class of PI3Ks are required.

# <span id="page-11-1"></span><span id="page-11-0"></span>**9 Class II PI3Ks, Immune Cells and Inflammatory Responses**

Very few data suggesting a possible role for class II PI3Ks in immune cells are available and some of them are summarised here. Evidence includes the observation that downregulation of PI3K-C2α reduced the FcεRI-mediated release of the enzyme β-hexosaminidase and a tagged neuropeptide-Y in RBL-2H3 cells (Nigorikawa et al. [2014\)](#page-16-15). These data, together with the detected localisation of  $PI3K-C2\alpha$  on large vesicles generated upon FcεRI stimulation, suggested that this enzyme is involved in FcεRI-mediated degranulation (Nigorikawa et al. [2014\)](#page-16-15).

A role for PI3K-C2 $\beta$  in the activation of the K<sup>+</sup> channel KCa3.1 was first suggested by the observation that siRNA-mediated downregulation of the enzyme inhibited the channel activity in Jurkat cells overexpressing KCa3.1 and in naïve human CD4+ T cells (Srivastava et al. [2009\)](#page-16-16). A specific role for PtdIns3*P* was also reported (Srivastava et al. [2009\)](#page-16-16), consistent with previous studies (Srivastava et al. [2005,](#page-16-17) [2006a](#page-16-18), [b](#page-16-19)). In addition, reduced FcεRI-mediated KCa3.1 activation was detected in bone marrowderived mast cells from PI3K-C2β knockout mice and this was rescued by dialysing a PtdIns3*P* able to insert into the plasma membrane (Srivastava et al. [2017\)](#page-17-14). Interestingly, stimulation with anti-CD3 antibodies did not appear to increase PI3K-C2β enzymatic activity in Jurkat cells overexpressing both KCa3.1 and a GFP-tagged PI3K-C2β, but it appeared to recruit the enzyme to the immunological synapse, suggesting that relocation of the enzyme was crucial to impact on KCa3.1 (Srivastava et al. [2009](#page-16-16)). Additional analysis confirmed an important role for this PI3K-C2β/PtdIns3*P*/KCa3.1 pathway in mast cell activation, as bone marrow-derived mast cells from PI3K-C2β knockout mice displayed reduced  $Ca^{2+}$  influx, cytokine production and degranulation upon FcεRI stimulation (Srivastava et al. [2017\)](#page-17-14). The additional observation that PI3K-C2β knockout mice were resistant to IgE-mediated passive cutaneous and systemic anaphylaxis led the authors to propose this enzyme as a potential therapeutic target for IgE-mediated diseases (Srivastava et al. [2017\)](#page-17-14).

Involvement of class II PI3Ks in inflammatory responses in pathological conditions are also suggested by some data in the literature, although the specific contribution of these enzymes is not always defined. For instance, a recent study reported increased expression of PI3K-C2 $\gamma$  in the synovial fluid of rheumatoid arthritis (RA) compared to osteoarthritis (OA) patients, in cells of the synovial lining layers and inflammatory infiltrates in the synovial tissue of RA compared to OA patients and in peripheral blood mononuclear cells from RA patients compared to healthy individuals (Kim et al. [2020\)](#page-15-18). These authors further demonstrated that the chemical compound PBT-6, which they showed inhibits  $P13K-C2\gamma$ , was able to increase cell death in tumour necrosis factor (TNF)-α-induced synovial fibroblasts (MH7A cells) and in lipopolysaccharide (LPS)-activated Raw 264.7 macrophages. Furthermore, PBT-6 decreased levels of interleukin (IL)-6 in TNF-α-treated MH7A cells and secretion of TNF-α and IL-6 by LPS-activated Raw 264.7. Migration of activated macrophages towards the conditioned medium of TNF-α-induced fibroblasts was

also inhibited by addition of PBT-6. Importantly, the authors showed that PBT-6 inhibited osteoclastogenesis in vitro and reduced severity of collagen-induced arthritis in mice (Kim et al. [2020\)](#page-15-18). On the other hand, a potential role for PI3K- $C2\alpha$  in OA has been suggested by a recent study reporting regulation of this enzyme by the potassium voltage-gated channel subfamily Q member 1 overlapping tran-script 1 in chondrocytes (Liu et al. [2021\)](#page-15-19). Specifically, the authors detected downregulation of the channel in osteoarthritic compared to normal chondrocytes and showed that overexpression of PI3K-C2α reduced the secretion of inflammatory factors, reduced apoptosis and increased viability of osteoarthritic chondrocytes. These observations suggest that deregulation of this pathway might be involved in development or progression of OA (Liu et al. [2021\)](#page-15-19).

A few observations suggesting a possible involvement of PI3K-C2β in the immune response in some pathological conditions also exist. Examples include a recent study evaluating the levels of nine tumour-infiltrating T cell types in hepatocellular carcinoma (HCC) and non-tumour tissues (Li et al. [2020](#page-15-20)). These authors suggested that driver genes including *PIK3C2B* might be associated with the reduced T cell infiltration detected in HCC (Li et al. [2020\)](#page-15-20). Similarly, *PIK3C2B* has been found to be one of only two genes whose expression levels seem to be able to discriminate chronic lymphocytic leukaemia and monoclonal B cell lymphocytosis cases from normal polyclonal and mono/oligoclonal B lymphocytes (McCarthy et al. [2015](#page-16-20)).

Additional evidence in the literature still requires further investigation in terms of their significance. An example includes the observation that the antioxidant delphinidin, which was shown to ameliorate psoriasis in vitro and in vivo, was also reported to bind to some kinases, including PI3K-C2β (Chamcheu et al. [2017](#page-14-18)). The importance of such an interaction and whether it is associated with the detected beneficial effects was not clarified.

Whether future studies will reveal additional roles for class II PI3Ks in immune response in physiological and/or pathological conditions remains to be established. In this respect, it is worth mentioning that a pool of PtdIns3*P*, whose synthesis is mediated by class III PI3K, is produced in phagosomes and is important for phagocytosis (Vieira et al. [2001](#page-17-17); Birkeland and Stenmark [2004;](#page-14-19) Ellson et al. [2001a\)](#page-14-20), in particular for modulation of the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase complex and superoxide production (Suh et al. [2006;](#page-17-18) Ellson et al. [2001b](#page-14-21)). In fact, the existence of cyclical waves of PtdIns3*P* synthesis during this process has been also reported (Chua and Deretic [2004\)](#page-14-22). Although the potential involvement of class II PI3Ks in modulating PtdIns3*P* levels in this process was excluded by a study investigating the regulation of the NADPH oxidase during phagocytosis of *Staphylococcus aureus* and *Escherichia coli* (Anderson et al. [2008](#page-13-10)), whether additional studies will provide further information on this topic remains to be seen.

Similarly, it has been reported that autophagy is important for the regulation of the innate immune system (Germic et al. [2019a,](#page-15-21) [b](#page-15-22)). Indeed, autophagy, a process generally used to degrade cellular components, such as damaged organelles or unnecessary and/or potentially harmful molecules, or to provide metabolic intermediates, can also provide materials for presentation by innate immune cells (Germic et al. [2019a\)](#page-15-21). The process requires generation of a double membrane structure named

<span id="page-13-1"></span>autophagosome and its fusion to lysosomes (Levine and Klionsky [2004;](#page-15-23) Zhao et al. [2021\)](#page-17-19) and several studies have established that synthesis of PtdIns3*P* by class III PI3K is critical for autophagosome formation (Nascimbeni et al. [2017b](#page-16-21); Backer [2008\)](#page-14-23). Emerging data in the literature, however, also point to the contribution of PI3K-C2 $\alpha$  to the process (Merrill et al. [2017](#page-16-9)), including recent evidence of a specific type of autophagy involving this enzyme (Bischoff et al. [2021\)](#page-14-24). It will be interesting to investigate whether class II PI3K-mediated autophagy plays any role in immune cells.

#### <span id="page-13-0"></span>**10 Conclusion**

Interest towards the identification of the physiological roles of class II PI3Ks and their potential involvement in human diseases has massively increased in the past fifteen years. This has led to a better understanding of the cellular functions regulated by these enzymes. On the other hand, some of the limitations that had previously hindered the investigation of class II PI3Ks still exist, namely the limited availability or lack of selectively inhibitors (Falasca et al. [2017](#page-15-24)), which has also strongly limited the impact and translational relevance of the accumulating lines of evidence pointing to their involvement in human diseases (Falasca et al. [2017](#page-15-24)). Much work is still required to shed more light into these PI3Ks and to fully understand their contribution to physiological and pathological processes.

#### <span id="page-13-2"></span>**References**

- <span id="page-13-8"></span>Abere B, Samarina N, Gramolelli S et al (2018) Kaposi's sarcoma-associated herpesvirus nonstructural membrane protein pK15 recruits the class II phosphatidylinositol 3-kinase PI3K-C2 $\alpha$  to activate productive viral replication. J Virol 92:e00544-e618
- <span id="page-13-5"></span>Alliouachene S, Bilanges B, Chicanne G et al (2015) Inactivation of the class II PI3K-C2β potentiates insulin signaling and sensitivity. Cell Rep 13:1881–1894
- <span id="page-13-7"></span>Alliouachene S, Bilanges B, Chaussade C et al (2016) Inactivation of class II PI3K-C2α induces leptin resistance, age-dependent insulin resistance and obesity in male mice. Diabetologia 59:1503–1512
- <span id="page-13-10"></span>Anderson KE, Boyle KB, Davidson K et al (2008) CD18-dependent activation of the neutrophil NADPH oxidase during phagocytosis of *Escherichia coli* or *Staphylococcus aureus* is regulated by class III but not class I or II PI3Ks. Blood 112:5202–5211
- <span id="page-13-3"></span>Arcaro A, Volinia S, Zvelebil MJ et al (1998) Human phosphoinositide 3-kinase C2beta, the role of calcium and the C2 domain in enzyme activity. J Biol Chem 273:33082–33090
- <span id="page-13-4"></span>Arcaro A, Zvelebil MJ, Wallasch C et al (2000) Class II phosphoinositide 3-kinases are downstream targets of activated polypeptide growth factor receptors. Mol Cell Biol 20:3817–3830
- <span id="page-13-6"></span>Arcaro A, Khanzada UK, Vanhaesebroeck B et al (2002) Two distinct phosphoinositide 3-kinases mediate polypeptide growth factor-stimulated PKB activation. EMBO J 21:5097–5108
- <span id="page-13-9"></span>Aung KT, Yoshioka K, Aki S et al (2019) The class II phosphoinositide 3-kinases PI3K-C2α and PI3K-C2β differentially regulate clathrin-dependent pinocytosis in human vascular endothelial cells. J Physiol Sci 69:263–280
- <span id="page-14-23"></span>Backer JM (2008) The regulation and function of class III PI3Ks: novel roles for Vps34. Biochem J 410:1–17
- <span id="page-14-4"></span>Bilanges B, Posor Y, Vanhaesebroeck B (2019) PI3K isoforms in cell signalling and vesicle trafficking. Nat Rev Mol Cell Biol 20:515–534
- <span id="page-14-19"></span>Birkeland HC, Stenmark H (2004) Protein targeting to endosomes and phagosomes via FYVE and PX domains. Curr Top Microbiol Immunol 282:89–115
- <span id="page-14-24"></span>Bischoff ME, Zang Y, Chu J et al (2021) Selective MAP1LC3C (LC3C) autophagy requires noncanonical regulators and the C-terminal peptide. J Cell Biol 220:e202004182
- <span id="page-14-8"></span>Boukhalfa A, Nascimbeni AC, Dupont N et al (2020a) Primary cilium-dependent autophagy drafts PIK3C2A to generate PtdIns3P in response to shear stress. Autophagy 16:1143–1144
- <span id="page-14-9"></span>Boukhalfa A, Nascimbeni AC, Ramel D et al (2020b) PI3KC2α-dependent and VPS34-independent generation of PI3P controls primary cilium-mediated autophagy in response to shear stress. Nat Commun 11:294
- <span id="page-14-10"></span>Braccini L, Ciraolo E, Campa CC et al (2015) PI3K-C2 $\gamma$  is a Rab5 effector selectively controlling endosomal Akt2 activation downstream of insulin signalling. Nat Commun 6:7400
- <span id="page-14-6"></span>Brown RA, Ho LK, Weber-Hall SJ et al (1997) Identification and cDNA cloning of a novel mammalian C2 domain-containing phosphoinositide 3-kinase, HsC2-PI3K. Biochem Biophys Res Commun 233:537–544
- <span id="page-14-0"></span>Cantley LC (2002) The phosphoinositide 3-kinase pathway. Science 296:1655–1657
- <span id="page-14-18"></span>Chamcheu JC, Adhami VM, Esnault S et al (2017) Dual inhibition of PI3K/Akt and mTOR by the dietary antioxidant, delphinidin, ameliorates psoriatic features in vitro and in an imiquimodinduced psoriasis-like disease in mice. Antioxid Redox Signal 26:49–69
- <span id="page-14-11"></span>Chen KE, Tillu VA, Chandra M et al (2018) Molecular basis for membrane recruitment by the PX and C2 domains of class II phosphoinositide 3-kinase-C2α. Structure 26:1612-1625.e4
- <span id="page-14-13"></span>Chiang TM, Postlethwaite AE (2006) Increase in phosphotidylinositide-3 kinase activity by nitrotyrosylation of lysates of platelets from patients with systemic sclerosis. Biochim Biophys Acta 1760:32–37
- <span id="page-14-16"></span>Chikh A, Ferro R, Abbott JJ et al (2016) Class II phosphoinositide 3-kinase C2β regulates a novel signaling pathway involved in breast cancer progression. Oncotarget 7:18325–18345
- <span id="page-14-22"></span>Chua J, Deretic V (2004) Mycobacterium tuberculosis reprograms waves of phosphatidylinositol 3-phosphate on phagosomal organelles. J Biol Chem 279:36982–36992
- <span id="page-14-17"></span>Cisse O, Quraishi M, Gulluni F et al (2019) Downregulation of class II phosphoinositide 3-kinase PI3K-C2β delays cell division and potentiates the effect of docetaxel on cancer cell growth. J Exp Clin Cancer Res 38:472
- <span id="page-14-7"></span>Consortium GTEx (2013) The genotype-tissue expression (GTEx) project. Nat Genet 45:580–585
- <span id="page-14-12"></span>Das M, Scappini E, Martin NP et al (2007) Regulation of neuron survival through an intersectinphosphoinositide 3' -kinase C2beta-AKT pathway. Mol Cell Biol 27:7906–7917
- <span id="page-14-1"></span>Domin J, Waterfield MD (1997) Using structure to define the function of phosphoinositide 3-kinase family members. FEBS Lett 410:91–95
- <span id="page-14-5"></span>Domin J, Pages F, Volinia S et al (1997) Cloning of a human phosphoinositide 3-kinase with a C2 domain that displays reduced sensitivity to the inhibitor wortmannin. Biochem J 326:139–147
- <span id="page-14-15"></span>Domin J, Harper L, Aubyn D et al (2005) The class II phosphoinositide 3-kinase PI3K-C2beta regulates cell migration by a PtdIns3P dependent mechanism. J Cell Physiol 205:452–462
- <span id="page-14-14"></span>Dominguez V, Raimondi C, Somanath S et al (2011) Class II phosphoinositide 3-kinase regulates exocytosis of insulin granules in pancreatic beta cells. J Biol Chem 286:4216–4225
- <span id="page-14-20"></span>Ellson CD, Anderson KE, Morgan G et al (2001a) Phosphatidylinositol 3-phosphate is generated in phagosomal membranes. Curr Biol 11:1631–1635
- <span id="page-14-21"></span>Ellson CD, Gobert-Gosse S, Anderson KE et al (2001b) PtdIns(3)P regulates the neutrophil oxidase complex by binding to the PX domain of p40(phox). Nat Cell Biol 3:679–682
- <span id="page-14-2"></span>Engelman JA, Luo J, Cantley LC (2006) The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 7:606–619
- <span id="page-14-3"></span>Falasca M, Maffucci T (2007) Role of class II phosphoinositide 3-kinase in cell signalling. Biochem Soc Trans 35:211–214
- <span id="page-15-2"></span>Falasca M, Maffucci T (2012) Regulation and cellular functions of class II phosphoinositide 3 kinases. Biochem J 443:587–601
- <span id="page-15-8"></span>Falasca M, Hughes WE, Dominguez V et al (2007) The role of phosphoinositide 3-kinase C2alpha in insulin signaling. J Biol Chem 282:28226–28236
- <span id="page-15-24"></span>Falasca M, Hamilton JR, Selvadurai M et al (2017) Class II phosphoinositide 3-kinases as novel drug targets. J Med Chem 60:47–65
- <span id="page-15-10"></span>Franco I, Gulluni F, Campa CC et al (2014) PI3K class II  $\alpha$  controls spatially restricted endosomal PtdIns3P and Rab11 activation to promote primary cilium function. Dev Cell 28:647–658
- <span id="page-15-13"></span>Franco I, Margaria JP, De Santis MC et al (2016) Phosphoinositide 3-kinase-C2α regulates polycystin-2 ciliary entry and protects against kidney cyst formation. J Am Soc Nephrol 27:1135–1144
- <span id="page-15-5"></span>Gaidarov I, Smith ME, Domin J et al (2001) The class II phosphoinositide 3-kinase C2alpha is activated by clathrin and regulates clathrin-mediated membrane trafficking. Mol Cell 7:443–449
- <span id="page-15-21"></span>Germic N, Frangez Z, Yousefi S et al (2019a) Regulation of the innate immune system by autophagy: neutrophils, eosinophils, mast cells, NK cells. Cell Death Differ 26:703–714
- <span id="page-15-22"></span>Germic N, Frangez Z, Yousefi S et al (2019b) Regulation of the innate immune system by autophagy: monocytes, macrophages, dendritic cells and antigen presentation. Cell Death Differ 26:715–727
- <span id="page-15-1"></span>Ghigo A, Morello F, Perino A et al (2012) Phosphoinositide 3-kinases in health and disease. Subcell Biochem 58:183–213
- <span id="page-15-7"></span>Gulluni F, Martini M, De Santis MC et al (2017) Mitotic spindle assembly and genomic stability in breast cancer require PI3K-C2α scaffolding function. Cancer Cell 32:444-459.e7
- <span id="page-15-3"></span>Gulluni F, De Santis MC, Margaria JP et al (2019) Class II PI3K functions in cell biology and disease. Trends Cell Biol 29:339–359
- <span id="page-15-12"></span>Harada K, Truong AB, Cai T et al (2005) The class II phosphoinositide 3-kinase C2beta is not essential for epidermal differentiation. Mol Cell Biol 25:11122–11130
- <span id="page-15-17"></span>Islam S, Yoshioka K, Aki S et al (2020) Class II phosphatidylinositol 3-kinase α and β isoforms are required for vascular smooth muscle Rho activation, contraction and blood pressure regulation in mice. J Physiol Sci 70:18
- <span id="page-15-16"></span>Katso RM, Pardo OE, Palamidessi A et al (2006) Phosphoinositide 3-kinase C2beta regulates cytoskeletal organization and cell migration via Rac-dependent mechanisms. Mol Biol Cell 17:3729–3744
- <span id="page-15-18"></span>Kim J, Jung KH, Yoo J et al (2020) PBT-6, a novel PI3K-C2 $\gamma$  inhibitor in rheumatoid arthritis. Biomol Ther (Seoul) 28:172–183
- <span id="page-15-14"></span>Krag C, Malmberg EK, Salcini AE (2010) PI3KC2 $\alpha$ , a class II PI3K, is required for dynaminindependent internalization pathways. J Cell Sci 123:4240–4250
- <span id="page-15-11"></span>Leibiger B, Moede T, Uhles S et al (2010) Insulin-feedback via PI3K-C2alpha activated PKBalpha/Akt1 is required for glucose-stimulated insulin secretion. FASEB J 24:1824–1837
- <span id="page-15-15"></span>Leibiger B, Moede T, Paschen M et al (2015) PI3K-C2α knockdown results in rerouting of insulin signaling and pancreatic beta cell proliferation. Cell Rep 13:15–22
- <span id="page-15-23"></span>Levine B, Klionsky DJ (2004) Development by self-digestion: molecular mechanisms and biological functions of autophagy. Dev Cell 6:463–477
- <span id="page-15-20"></span>Li J, Zhou J, Kai S et al (2020) Functional and clinical characterization of tumor-infiltrating T cell subpopulations in hepatocellular carcinoma. Front Genet 11:586415
- <span id="page-15-19"></span>Liu Y, Zhao D, Wang X et al (2021) LncRNA KCNQ1OT1 attenuates osteoarthritic chondrocyte dysfunction via the miR-218-5p/PIK3C2A axis. Cell Tissue Res 385:115–126
- <span id="page-15-4"></span>MacDougall LK, Domin J, Waterfield MD (1995) A family of phosphoinositide 3-kinases in *Drosophila* identifies a new mediator of signal transduction. Curr Biol 5:1404–1415
- <span id="page-15-0"></span>Maffucci T (2012) An introduction to phosphoinositides. Curr Top Microbiol Immunol 362:1–42
- <span id="page-15-9"></span>Maffucci T, Cooke FT, Foster FM et al (2005) Class II phosphoinositide 3-kinase defines a novel signaling pathway in cell migration. J Cell Biol 169:789–799
- <span id="page-15-6"></span>Marat AL, Wallroth A, Lo WT et al (2017) mTORC1 activity repression by late endosomal phosphatidylinositol 3,4-bisphosphate. Science 356:968–972
- <span id="page-16-0"></span>Margaria JP, Ratto E, Gozzelino L et al (2019) Class II PI3Ks at the intersection between signal transduction and membrane trafficking. Biomolecules 9:104
- <span id="page-16-12"></span>Mavrommati I, Cisse O, Falasca M et al (2016) Novel roles for class II phosphoinositide 3-kinase C2β in signalling pathways involved in prostate cancer cell invasion. Sci Rep 6:23277
- <span id="page-16-20"></span>McCarthy BA, Yancopoulos S, Tipping M et al (2015) A seven-gene expression panel distinguishing clonal expansions of pre-leukemic and chronic lymphocytic leukemia B cells from normal B lymphocytes. Immunol Res 63:90–100
- <span id="page-16-9"></span>Merrill NM, Schipper JL, Karnes JB et al (2017) PI3K-C2α knockdown decreases autophagy and maturation of endocytic vesicles. PLoS ONE 12:e0184909
- <span id="page-16-7"></span>Meunier FA, Osborne SL, Hammond GR et al (2005) Phosphatidylinositol 3-kinase C2alpha is essential for ATP-dependent priming of neurosecretory granule exocytosis. Mol Biol Cell 16:4841–4851
- <span id="page-16-3"></span>Misawa H, Ohtsubo M, Copeland NG et al (1998) Cloning and characterization of a novel class II phosphoinositide 3-kinase containing C2 domain. Biochem Biophys Res Commun 244:531–539
- <span id="page-16-5"></span>Mountford JK, Petitjean C, Putra HW et al (2015) The class II PI 3-kinase, PI3KC2α, links platelet internal membrane structure to shear-dependent adhesive function. Nat Commun 6:6535
- <span id="page-16-10"></span>Nascimbeni AC, Codogno P, More E (2017a) Phosphatidylinositol-3-phosphate in the regulation of autophagy membrane dynamics. FEBS J 284:1267–1278
- <span id="page-16-21"></span>Nascimbeni AC, Codogno P, Morel E (2017b) Phosphatidylinositol-3-phosphate in the regulation of autophagy membrane dynamics. FEBS J 284:1267–1278
- <span id="page-16-15"></span>Nigorikawa K, Hazeki K, Guo Y et al (2014) Involvement of class II phosphoinositide 3-kinase α-isoform in antigen-induced degranulation in RBL-2H3 cells. PLoS ONE 9:e111698
- <span id="page-16-13"></span>O'Hanlon R, Leyva-Grado VH, Sourisseau M et al (2019) An influenza virus entry inhibitor targets class II PI3 kinase and synergizes with oseltamivir. ACS Infect Dis 5:1779–1793
- <span id="page-16-2"></span>Ono F, Nakagawa T, Saito S et al (1998) A novel class II phosphoinositide 3-kinase predominantly expressed in the liver and its enhanced expression during liver regeneration. J Biol Chem 273:7731–7736
- <span id="page-16-6"></span>Petitjean C, Setiabakti NM, Mountford JK et al (2016) Combined deficiency of PI3KC2α and PI3KC2β reveals a nonredundant role for PI3KC2α in regulating mouse platelet structure and thrombus stability. Platelets 27:402–409
- <span id="page-16-8"></span>Polachek WS, Moshrif HF, Franti M et al (2016) High-throughput small interfering RNA screening identifies phosphatidylinositol 3-kinase class II alpha as important for production of human cytomegalovirus virions. J Virol 90:8360–8371
- <span id="page-16-4"></span>Posor Y, Eichhorn-Gruenig M, Puchkov D et al (2013) Spatiotemporal control of endocytosis by phosphatidylinositol-3,4-bisphosphate. Nature 499:233–237
- <span id="page-16-11"></span>Roberts R, Ktistakis NT (2013) Omegasomes: PI3P platforms that manufacture autophagosomes. Essays Biochem 55:17–27
- <span id="page-16-1"></span>Rozycka M, Lu YJ, Brown RA et al (1998) cDNA cloning of a third human C2-domain-containing class II phosphoinositide 3-kinase, PI3K-C2gamma, and chromosomal assignment of this gene (PIK3C2G) to 12p12. Genomics 54:569–574
- <span id="page-16-14"></span>Sarker MAK, Aki S, Yoshioka K et al (2019) Class II PI3Ks α and β are required for Rho-dependent uterine smooth muscle contraction and parturition in mice. Endocrinology 160:235–248
- <span id="page-16-17"></span>Srivastava S, Li Z, Lin L et al (2005) The phosphatidylinositol 3-phosphate phosphatase myotubularin-related protein 6 (MTMR6) is a negative regulator of the  $Ca^{2+}$ -activated K<sup>+</sup> channel KCa3.1. Mol Cell Biol 25:3630–3638
- <span id="page-16-18"></span>Srivastava S, Choudhury P, Li Z et al (2006a) Phosphatidylinositol 3-phosphate indirectly activates KCa3.1 via 14 amino acids in the carboxy terminus of KCa3.1. Mol Biol Cell 17:146–154
- <span id="page-16-19"></span>Srivastava S, Ko K, Choudhury P et al (2006b) Phosphatidylinositol-3 phosphatase myotubularinrelated protein 6 negatively regulates CD4 T cells. Mol Cell Biol 26:5595–5602
- <span id="page-16-16"></span>Srivastava S, Di L, Zhdanova O et al (2009) The class II phosphatidylinositol 3 kinase C2beta is required for the activation of the  $K^+$  channel KCa3.1 and CD4 T-cells. Mol Biol Cell 20:3783– 3791
- <span id="page-17-14"></span>Srivastava S, Li Z, Skolnik EY (2017) Phosphatidlyinositol-3-kinase C2 beta (PI3KC2β) is a potential new target to treat IgE mediated disease. PLoS ONE 12:e0183474
- <span id="page-17-18"></span>Suh CI, Stull ND, Li XJ et al (2006) The phosphoinositide-binding protein p40phox activates the NADPH oxidase during FcgammaIIA receptor-induced phagocytosis. J Exp Med 203:1915–1925
- <span id="page-17-16"></span>Tibolla G, Piñeiro R, Chiozzotto D et al (2013) Class II phosphoinositide 3-kinases contribute to endothelial cells morphogenesis. PLoS ONE 8:e53808
- <span id="page-17-4"></span>Tiosano D, Baris HN, Chen A et al (2019) Mutations in PIK3C2A cause syndromic short stature, skeletal abnormalities, and cataracts associated with ciliary dysfunction. PLoS Genet 15:e1008088
- <span id="page-17-8"></span>Valet C, Chicanne G, Severac C et al (2015) Essential role of class II PI3K-C2α in platelet membrane morphology. Blood 126:1128–1137
- <span id="page-17-1"></span>Vanhaesebroeck B, Leevers SJ, Ahmadi K et al (2001) Synthesis and function of 3-phosphorylated inositol lipids. Annu Rev Biochem 70:535–602
- <span id="page-17-2"></span>Vanhaesebroeck B, Guillermet-Guibert J, Graupera M et al (2010) The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol 11:329–341
- <span id="page-17-0"></span>Vanhaesebroeck B, Stephens L, Hawkins P (2012) PI3K signalling: the path to discovery and understanding. Nat Rev Mol Cell Biol 13:195–203
- <span id="page-17-3"></span>Vanhaesebroeck B, Whitehead MA, Piñeiro R (2016) Molecules in medicine mini-review: isoforms of PI3K in biology and disease. J Mol Med (Berlin) 94:5–11
- <span id="page-17-17"></span>Vieira OV, Botelho RJ, Rameh L et al (2001) Distinct roles of class I and class III phosphatidylinositol 3-kinases in phagosome formation and maturation. J Cell Biol 155:19–25
- <span id="page-17-6"></span>Virbasius JV, Guilherme A, Czech MP (1996) Mouse p170 is a novel phosphatidylinositol 3-kinase containing a C2 domain. J Biol Chem 271:13304–13307
- <span id="page-17-10"></span>Visnjić D, Curić J, Crljen V et al (2003) Nuclear phosphoinositide 3-kinase C2beta activation during G2/M phase of the cell cycle in HL-60 cells. Biochim Biophys Acta 1631:61–71
- <span id="page-17-13"></span>Wallroth A, Koch PA, Marat AL et al (2019) Protein kinase N controls a lysosomal lipid switch to facilitate nutrient signalling via mTORC1. Nat Cell Biol 21:1093–1101
- <span id="page-17-12"></span>Wang Y, Yoshioka K, Azam MA et al (2006) Class II phosphoinositide 3-kinase alpha-isoform regulates Rho, myosin phosphatase and contraction in vascular smooth muscle. Biochem J 394:581–592
- <span id="page-17-11"></span>Wang H, Lo WT, Vujičić Žagar A et al (2018) Autoregulation of class II alpha PI3K activity by its lipid-binding PX-C2 domain module. Mol Cell 71:343-351.e4
- <span id="page-17-7"></span>Wen PJ, Osborne SL, Morrow IC et al  $(2008)$  Ca<sup>2+</sup>-regulated pool of phosphatidylinositol-3phosphate produced by phosphatidylinositol 3-kinase C2alpha on neurosecretory vesicles. Mol Biol Cell 19:5593–5603
- <span id="page-17-5"></span>Wheeler M, Domin J (2006) The N-terminus of phosphoinositide 3-kinase-C2beta regulates lipid kinase activity and binding to clathrin. J Cell Physiol 206:586–593
- <span id="page-17-15"></span>Yoshioka K, Sugimoto N, Takuwa N et al (2007) Essential role for class II phosphoinositide 3 kinase alpha-isoform in  $Ca^{2+}$ -induced, Rho- and Rho kinase-dependent regulation of myosin phosphatase and contraction in isolated vascular smooth muscle cells. Mol Pharmacol 71:912–920
- <span id="page-17-9"></span>Yoshioka K, Yoshida K, Cui H et al (2012) Endothelial PI3K-C2α, a class II PI3K, has an essential role in angiogenesis and vascular barrier function. Nat Med 18:1560–1569
- <span id="page-17-19"></span>Zhao YG, Codogno P, Zhang H (2021) Machinery, regulation and pathophysiological implications of autophagosome maturation. Nat Rev Mol Cell Biol 23:1–18